Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation
AN Khan, A Chowdhury, A Karulkar… - Frontiers in …, 2022 - frontiersin.org
Chimeric antigen receptor T cell (CAR-T) therapy demonstrated remarkable success in long-
term remission of cancers and other autoimmune diseases. Currently, six products (Kymriah …
term remission of cancers and other autoimmune diseases. Currently, six products (Kymriah …
CAR‐T cell therapy in hematological malignancies: Where are we now and where are we heading for?
AN Khan, S Asija, J Pendhari… - European Journal of …, 2024 - Wiley Online Library
Chimeric antigen receptor T (CAR‐T) therapy has emerged as a revolutionary new pillar in
cancer care, particularly in relapsed/refractory (r/r) B‐cell malignancies. Following …
cancer care, particularly in relapsed/refractory (r/r) B‐cell malignancies. Following …
Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds
S Asija, A Chatterjee, S Yadav, G Chekuri… - International Reviews …, 2022 - Taylor & Francis
The aggressive and recurrent nature of glioblastoma is multifactorial and has been attributed
to its biological heterogeneity, dysfunctional metabolic signaling pathways, rigid blood–brain …
to its biological heterogeneity, dysfunctional metabolic signaling pathways, rigid blood–brain …
[HTML][HTML] Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL
F Song, Y Hu, Y Zhang, M Zhang, T Yang… - … for Immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background Murine chimeric antigen receptor T (CAR-T) cell therapy has demonstrated
clinical benefit in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia …
clinical benefit in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia …
Development of a novel anti-CD19 CAR containing a fully human scFv and three costimulatory domains
Y Wutti-In, J Sujjitjoon, N Sawasdee, A Panya… - Frontiers in …, 2022 - frontiersin.org
Second-generation anti-CD19-chimeric antigen receptor T cells (anti-CD19-CAR2 T cells)
are effective for treating B-cell malignancies; however, anti-CD19-CAR2 T cells can induce …
are effective for treating B-cell malignancies; however, anti-CD19-CAR2 T cells can induce …
15‐color highly sensitive flow cytometry assay for post anti‐CD19 targeted therapy (anti‐CD19‐CAR‐T and blinatumomab) measurable residual disease assessment …
G Chatterjee, P Dhende, S Raj, V Shetty… - European Journal of …, 2024 - Wiley Online Library
Objectives Measurable residual disease (MRD) is the most relevant predictor of disease‐
free survival in B‐cell acute lymphoblastic leukemia (B‐ALL). We aimed to establish a highly …
free survival in B‐cell acute lymphoblastic leukemia (B‐ALL). We aimed to establish a highly …
Leveraging the immunoinformatics approach for designing the SARS-CoV-2 Omicron-specific antigenic cassette of mRNA vaccine
R Wadapurkar, S Singh, A Singh - Vaccine, 2024 - Elsevier
Abstract Emergence of SARS-CoV-2 Omicron variant has presented a significant challenge
to global health, demanding rapid development of mRNA-based vaccines. The mRNA …
to global health, demanding rapid development of mRNA-based vaccines. The mRNA …
[HTML][HTML] 人源化靶向CD19 CAR-T 细胞治疗复发/难治急性B 淋巴细胞白血病的有效性及安全性
宋凤美， 胡永仙， 张明明， 吴文俊， 徐惠君… - Chinese Journal of …, 2022 - ncbi.nlm.nih.gov
人源化靶向CD19 CAR-T细胞治疗复发/难治急性B淋巴细胞白血病的有效性及安全性- PMC Back
to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage …
to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage …
CAR-T cell therapy in India requires a paradigm shift in training, education and health care processes
A Ravindranath, A Dubey, S Suresh, G Chaudhuri… - Cytotherapy, 2022 - Elsevier
Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of some
kinds of cancers. Hundreds of companies and academic institutions are collaborating to …
kinds of cancers. Hundreds of companies and academic institutions are collaborating to …
[HTML][HTML] Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies
WC Temple, MA Nix, A Naik, A Izgutdina… - … for Immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background Approximately 50% of patients who receive anti-CD19 CAR-T cells relapse,
and new immunotherapeutic targets are urgently needed. We recently described CD72 as a …
and new immunotherapeutic targets are urgently needed. We recently described CD72 as a …